ClinicalTrials.gg
CompletedNCT05890105Updated Jan 3, 2025Results posted

A Study to Learn About the Study Medicine PF-07853578 and How it Acts in the Bodies of Healthy Adults

A Phase 1 interventional study of PF-07853578 and Placebo in Healthy Participants, sponsored by Pfizer. Completed at 2 sites in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-01-03.

Sponsored by Pfizer · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
23
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purposes of this study are:

  • To see how the new medicine (PF-07853578) under study is tolerated. And if there are any important side effects. And, how people feel after taking single increasing amount of the medicine by mouth.
  • To measure the amount of study medicine in your blood after the medicine is taken by mouth.

This study is seeking for participants who:

  • are females of 18 to 65 years old and are not able to give birth to a child.
  • are males of 18 to 65 years old.
  • have body mass index of 16 to 31 kilograms per meter squared.
  • have a total body weight of more than 50 kilograms (110 pounds). Participants will be randomly selected to receive either study medicine (PF-07853578) or placebo (a pill that has no medicine in it). Participants may receive up to 4 amounts of study medicine and up to 2 amounts of placebo.
02

Conditions studied

  • Healthy Participants
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 148 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Female participants of non- and male participants aged 18 to 65 years at screening who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring.
  2. of 16 to 30.5 kg/m2; and a total body weight >50 kg (110 lb).

Exclusion criteria

Exclusion Criteria:

  1. Evidence or history of hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).
  2. Use of prescription or nonprescription drugs and dietary and herbal supplements within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study intervention, with the exception of moderate or strong cytochrome P450 3A () inducers or inhibitors which are prohibited within 14 days plus 5 half-lives prior to the first dose of study intervention.
  3. Previous administration with an product (drug or vaccine) within 30 days (or as determined by the local requirement) or 5 half lives preceding the first dose of study intervention used in this study (whichever is longer). Participation in studies of other investigational products (drug or vaccine) at any time during their participation in this study.
  4. Screening supine blood pressure (BP) ≥140 mm Hg (systolic) or ≥90 mm Hg (diastolic) for participants \<60 years; and ≥150/90 mm/Hg for participants ≥60 years old, following at least 5 minutes of supine rest.
  5. Renal impairment as defined by an estimated (eGFR) of \<75 mL/min/1.73m².
  6. Hematuria as defined by >1+ heme on urine dipstick.
  7. Albuminuria as defined by albumin/creatine (Cr) ratio on spot urine albumin (UA) >30 mg/g.
  8. Standard 12 lead that demonstrates clinically relevant abnormalities that may affect participant safety or interpretation of study results.
  9. Participants with ANY of the following abnormalities in clinical laboratory tests at screening, as assessed by the study specific laboratory and confirmed by a single repeat test, if deemed necessary:

    • (ALT), aspartate aminotransferase (AST), ≥1.05×.
    • Total cholesterol, triglycerides, or direct LDL ≥1.25×ULN.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
23 participants (actual)

Study arms

  • Experimental
    Cohort 1

    Single dose administration of PF-07853578 and placebo. Participants will receive up to 4 dose levels of PF-07853578 and up to 2 dose levels of matching placebo.

    Drug: PF-07853578 · Drug: Placebo

  • Experimental
    Cohort 2

    Single dose administration of PF-07853578 and placebo. Participants will receive up to 4 dose levels of PF-07853578 and up to 2 dose levels of matching placebo.

    Drug: PF-07853578 · Drug: Placebo

  • Experimental
    Cohort 3

    Single dose administration of PF-07853578 and placebo. Participants will receive up to 4 dose levels of PF-07853578 and up to 2 dose levels of matching placebo.

    Drug: PF-07853578 · Drug: Placebo

Interventions

  • DrugPF-07853578

    PF-07853578 will be administered as oral solutions or suspensions as escalating single doses to be determined.

  • DrugPlacebo

    Placebo will be administered as oral solutions or suspensions as escalating single doses to be determined.

06

What researchers measure

Primary outcomes

  1. Number of Participants Reporting Treatment-Emergent Adverse Events (TEAEs)

    An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An adverse event is considered a TEAE if the event started during the effective duration of treatment. All events that started on or after the first dosing day and time/start time, if collected, but before the end of the study were flagged as TEAEs. The algorithm did not consider any events that started prior to the first dose date. Treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.

    Time frame: Day 1-11 in each period, along with the 29-36 day post final dose follow-up

  2. Number of Participants With Clinical Laboratory Abnormalities Meeting Pre-Defined Categorical Criteria Without Regard to Baseline Abnormality

    Pre-defined categorical criteria for laboratory abnormalities included: Lymphocytes \<0.8 x lower limit of normal (LLN); Basophils/Leukocytes \> 1.2 x upper limit of normal (ULN); Eosinophils/Leukocytes \>1.2 x ULN; Monocytes/Leukocytes \>1.2 x ULN; low-density lipoprotein (LDL) Direct Endpoint Measure \>1.2 x ULN; Triglycerides \>1.3 x ULN; Specific Gravity \<1.003 or \>1.030; pH \>8; Ketones ≥1; Urobilinogen (EU) ≥1; URINE Bilirubin ≥1; Leukocyte Esterase ≥1.

    Time frame: Day 1-11 in each period, along with the 29-36 day post final dose follow-up

  3. Number of Participants With Vital Signs Abnormalities Meeting Pre-Defined Categorical Criteria

    Vital signs categorical criteria: 1) supine systolic blood pressure (SBP) \<90 millimeters of mercury (mmHg); 2) supine diastolic blood pressure (DBP) \<50 mmHg; 3) supine pulse rate \<40 or \>120 beats per minute (bpm); 4) change from baseline (increase or decrease) in supine SBP greater than or equal to (≥) 30 mmHg; 5) change from baseline (increase or decrease) in supine DBP ≥ 20 mmHg.

    Time frame: Day 1-11 in each period, along with the 29-36 day post final dose follow-up

  4. Number of Participants With Abnormal Electrocardiogram (ECG) Meeting Pre-Defined Categorical Criteria

    ECG categorical criteria: 1. PR interval (the interval between the start of the P wave and the start of the QRS complex, corresponding to the time between the onset of the atrial depolarization and onset of ventricular depolarization): a) ≥300 millisecond (msec), b) ≥25% increase when baseline is \> 200 msec, c) ≥50% increase when baseline is less than or equal to (≤) 200 msec. 2\. QRS interval (time from ECG Q wave to the end of the S wave corresponding to ventricle depolarization): a) ≥140 msec, b) ≥50% increase from baseline. 3\. QTcF interval (QT corrected using the Fridericia formula): a) \>450 msec and ≤480 msec, b) \>480 msec and ≤500 msec, c) \>500 msec, d) \>30 msec and ≤60 msec increase from baseline, e) \>60 msec increase from baseline.

    Time frame: Day 1-11 in each period, along with the 29-36 day post final dose follow-up

Secondary outcomes

  1. Maximum Concentration Observed in Plasma (Cmax)

    Maximum observed plasma PF-07328948 concentration. Observed directly from data.

    Time frame: Pre-dose (0 hour) and 0.5 hour, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours and 12 hours post Day 1 dosing of each treatment period (Periods 1-4)

  2. Time to Achieve Cmax (Tmax)

    Observed directly from data as time of first occurrence.

    Time frame: Pre-dose (0 hour) and 0.5 hour, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours and 12 hours post Day 1 dosing of each treatment period (Periods 1-4)

  3. Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Measured Concentration (AUClast)

    Area under the plasma concentration time-curve from zero to the last measured concentration. It was determined by using linear/Log trapezoidal method.

    Time frame: Pre-dose (0 hours) and 0.5 hour, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours and 12 hours post Day 1 dosing of each treatment period (Periods 1-4)

  4. Area Under the Plasma Concentration-Time Curve From Time Zero to Extrapolated Infinite Time (AUCinf)

    Area under the plasma concentration-time curve from time 0 extrapolated to infinite time. AUCinf = AUClast + (Clast\*/kel), where Clast\* was the predicted plasma concentration at the last quantifiable timepoint estimated from the log-linear regression analysis, and Kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve, AUClast = Area under the plasma concentration time-curve from zero to the last measured concentration.

    Time frame: Pre-dose (0 hour) and 0.5 hour, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours and 12 hours post Day 1 dosing of each treatment period (Periods 1-4)

  5. Terminal Half-Life (t1/2)

    Terminal elimination half-life. t1/2 = Loge(2)/kel, where kel is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve. Only those data points judged to describe the terminal log linear decline were used in the regression.

    Time frame: Pre-dose (0 hour) and 0.5 hour, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours and 12 hours post Day 1 dosing of each treatment period (Periods 1-4)

07

Results

Posted Jan 3, 2025
Limitations and caveats
Any untoward findings identified on physical and/or neurological examinations, and cardiac monitoring conducted during the active collection period were captured as adverse events, if those findings met the definition of an AE.

Participant flow

Participant flow — Overall Study
MilestoneCohort 1Cohort 2Cohort 3
Started887
Completed667
Not completed220
Withdrew: Adverse event100
Withdrew: Other120

Outcome measures

PrimaryNumber of Participants Reporting Treatment-Emergent Adverse Events (TEAEs)

An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An adverse event is considered a TEAE if the event started during the effective duration of treatment. All events that started on or after the first dosing day and time/start time, if collected, but before the end of the study were flagged as TEAEs. The algorithm did not consider any events that started prior to the first dose date. Treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.

Time frame:
Day 1-11 in each period, along with the 29-36 day post final dose follow-up
Reported as:
Count of participants · Participants
Number of Participants Reporting Treatment-Emergent Adverse Events (TEAEs)
ParticipantsPF-07853578 1 mg (1mg) (Low Dosage Strength [LDS] Solution)3 mg8 mg8 mg (Intermediate Dosage Strength [IDS] Solution)10 mg30 mg100 mg300 mg300 mg Fed500 mgPlacebo FastedPlacebo Fed
All-causality AEs123221014030
Treatment-related AEs001020000010
All-causality SAEs000000000000
Treatment-related SAEs000000000000
PrimaryNumber of Participants With Clinical Laboratory Abnormalities Meeting Pre-Defined Categorical Criteria Without Regard to Baseline Abnormality

Pre-defined categorical criteria for laboratory abnormalities included: Lymphocytes \<0.8 x lower limit of normal (LLN); Basophils/Leukocytes \> 1.2 x upper limit of normal (ULN); Eosinophils/Leukocytes \>1.2 x ULN; Monocytes/Leukocytes \>1.2 x ULN; low-density lipoprotein (LDL) Direct Endpoint Measure \>1.2 x ULN; Triglycerides \>1.3 x ULN; Specific Gravity \<1.003 or \>1.030; pH \>8; Ketones ≥1; Urobilinogen (EU) ≥1; URINE Bilirubin ≥1; Leukocyte Esterase ≥1.

Time frame:
Day 1-11 in each period, along with the 29-36 day post final dose follow-up
Reported as:
Count of participants · Participants
Number of Participants With Clinical Laboratory Abnormalities Meeting Pre-Defined Categorical Criteria Without Regard to Baseline Abnormality
ParticipantsPF-07853578 1 mg (1mg) (Low Dosage Strength [LDS] Solution)3 mg8 mg8 mg (Intermediate Dosage Strength [IDS] Solution)10 mg30 mg100 mg300 mg300 mg Fed500 mgPlacebo FastedPlacebo Fed
Number of Participants With Clinical Laboratory Abnormalities Meeting Pre-Defined Categorical Criteria Without Regard to Baseline Abnormality4554554421111
PrimaryNumber of Participants With Vital Signs Abnormalities Meeting Pre-Defined Categorical Criteria

Vital signs categorical criteria: 1) supine systolic blood pressure (SBP) \<90 millimeters of mercury (mmHg); 2) supine diastolic blood pressure (DBP) \<50 mmHg; 3) supine pulse rate \<40 or \>120 beats per minute (bpm); 4) change from baseline (increase or decrease) in supine SBP greater than or equal to (≥) 30 mmHg; 5) change from baseline (increase or decrease) in supine DBP ≥ 20 mmHg.

Time frame:
Day 1-11 in each period, along with the 29-36 day post final dose follow-up
Reported as:
Count of participants · Participants
Number of Participants With Vital Signs Abnormalities Meeting Pre-Defined Categorical Criteria
ParticipantsPF-07853578 1 mg (1mg) (Low Dosage Strength [LDS] Solution)3 mg8 mg8 mg (Intermediate Dosage Strength [IDS] Solution)10 mg30 mg100 mg300 mg300 mg Fed500 mgPlacebo FastedPlacebo Fed
DBP <50 mmHg000000001000
Pulse rate < 40 bpm010001000000
Pulse rate > 120 bpm000000000000
SBP <90 mmHg001000021000
Change from baseline in DBP ≥20 increase000000000000
Change from baseline in DBP ≥20 decrease000000000010
Change from baseline in SBP ≥30 mmHg increase000000000000
Change from baseline in SBP ≥30 mmHg decrease000000000010
PrimaryNumber of Participants With Abnormal Electrocardiogram (ECG) Meeting Pre-Defined Categorical Criteria

ECG categorical criteria: 1. PR interval (the interval between the start of the P wave and the start of the QRS complex, corresponding to the time between the onset of the atrial depolarization and onset of ventricular depolarization): a) ≥300 millisecond (msec), b) ≥25% increase when baseline is \> 200 msec, c) ≥50% increase when baseline is less than or equal to (≤) 200 msec. 2\. QRS interval (time from ECG Q wave to the end of the S wave corresponding to ventricle depolarization): a) ≥140 msec, b) ≥50% increase from baseline. 3\. QTcF interval (QT corrected using the Fridericia formula): a) \>450 msec and ≤480 msec, b) \>480 msec and ≤500 msec, c) \>500 msec, d) \>30 msec and ≤60 msec increase from baseline, e) \>60 msec increase from baseline.

Time frame:
Day 1-11 in each period, along with the 29-36 day post final dose follow-up
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Electrocardiogram (ECG) Meeting Pre-Defined Categorical Criteria
ParticipantsPF-07853578 1 mg (1mg) (Low Dosage Strength [LDS] Solution)3 mg8 mg8 mg (Intermediate Dosage Strength [IDS] Solution)10 mg30 mg100 mg300 mg300 mg Fed500 mgPlacebo FastedPlacebo Fed
Number of Participants With Abnormal Electrocardiogram (ECG) Meeting Pre-Defined Categorical Criteria010000000000
SecondaryMaximum Concentration Observed in Plasma (Cmax)

Maximum observed plasma PF-07328948 concentration. Observed directly from data.

Time frame:
Pre-dose (0 hour) and 0.5 hour, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours and 12 hours post Day 1 dosing of each treatment period (Periods 1-4)
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
Maximum Concentration Observed in Plasma (Cmax)
nanogram per milliliter (ng/mL)PF-07853578 1 mg (1mg) (Low Dosage Strength [LDS] Solution)3 mg8 mg8 mg (Intermediate Dosage Strength [IDS] Solution)10 mg30 mg100 mg300 mg300 mg Fed500 mg
Maximum Concentration Observed in Plasma (Cmax)7.196 ± 147.226 ± 5214.87 ± 6641.92 ± 4117.92 ± 3543.91 ± 45119.8 ± 38355.6 ± 39690.6 ± 53449.2 ± 51
SecondaryTime to Achieve Cmax (Tmax)

Observed directly from data as time of first occurrence.

Time frame:
Pre-dose (0 hour) and 0.5 hour, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours and 12 hours post Day 1 dosing of each treatment period (Periods 1-4)
Reported as:
Median · hours (hr)
Time to Achieve Cmax (Tmax)
hours (hr)PF-07853578 1 mg (1mg) (Low Dosage Strength [LDS] Solution)3 mg8 mg8 mg (Intermediate Dosage Strength [IDS] Solution)10 mg30 mg100 mg300 mg300 mg Fed500 mg
Time to Achieve Cmax (Tmax)0.500 (0.500 to 1.00)1.08 (0.500 to 1.17)1.00 (0.500 to 1.00)0.517 (0.500 to 0.517)1.00 (0.500 to 2.00)2.00 (1.00 to 2.00)3.00 (2.00 to 3.02)2.00 (1.00 to 3.00)4.00 (2.00 to 6.00)3.02 (2.00 to 6.00)
SecondaryArea Under the Plasma Concentration-Time Curve From Time Zero to the Last Measured Concentration (AUClast)

Area under the plasma concentration time-curve from zero to the last measured concentration. It was determined by using linear/Log trapezoidal method.

Time frame:
Pre-dose (0 hours) and 0.5 hour, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours and 12 hours post Day 1 dosing of each treatment period (Periods 1-4)
Reported as:
Geometric mean · nanogram*hour per milliliter (ng*hr/mL)
Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Measured Concentration (AUClast)
nanogram*hour per milliliter (ng*hr/mL)PF-07853578 1 mg (1mg) (Low Dosage Strength [LDS] Solution)3 mg8 mg8 mg (Intermediate Dosage Strength [IDS] Solution)10 mg30 mg100 mg300 mg300 mg Fed500 mg
Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Measured Concentration (AUClast)17.03 ± 3043.52 ± 77105.8 ± 62111.6 ± 44153.3 ± 33462.4 ± 541825 ± 314590 ± 586747 ± 667774 ± 25
SecondaryArea Under the Plasma Concentration-Time Curve From Time Zero to Extrapolated Infinite Time (AUCinf)

Area under the plasma concentration-time curve from time 0 extrapolated to infinite time. AUCinf = AUClast + (Clast\*/kel), where Clast\* was the predicted plasma concentration at the last quantifiable timepoint estimated from the log-linear regression analysis, and Kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve, AUClast = Area under the plasma concentration time-curve from zero to the last measured concentration.

Time frame:
Pre-dose (0 hour) and 0.5 hour, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours and 12 hours post Day 1 dosing of each treatment period (Periods 1-4)
Reported as:
Geometric mean · ng*hr/mL
Area Under the Plasma Concentration-Time Curve From Time Zero to Extrapolated Infinite Time (AUCinf)
ng*hr/mLPF-07853578 1 mg (1mg) (Low Dosage Strength [LDS] Solution)3 mg8 mg8 mg (Intermediate Dosage Strength [IDS] Solution)10 mg30 mg100 mg300 mg300 mg Fed500 mg
Area Under the Plasma Concentration-Time Curve From Time Zero to Extrapolated Infinite Time (AUCinf)18.29 ± 3146.69 ± 73111.5 ± 60114.1 ± 44157.0 ± 33470.6 ± 551876 ± 294649 ± 596822 ± 678066 ± 27
SecondaryTerminal Half-Life (t1/2)

Terminal elimination half-life. t1/2 = Loge(2)/kel, where kel is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve. Only those data points judged to describe the terminal log linear decline were used in the regression.

Time frame:
Pre-dose (0 hour) and 0.5 hour, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours and 12 hours post Day 1 dosing of each treatment period (Periods 1-4)
Reported as:
Mean · hours (hr)
Terminal Half-Life (t1/2)
hours (hr)PF-07853578 1 mg (1mg) (Low Dosage Strength [LDS] Solution)3 mg8 mg8 mg (Intermediate Dosage Strength [IDS] Solution)10 mg30 mg100 mg300 mg300 mg Fed500 mg
Terminal Half-Life (t1/2)5.748 ± 4.122712.78 ± 3.698315.19 ± 7.12738.692 ± 2.427811.26 ± 4.782513.15 ± 2.599013.00 ± 3.860110.44 ± 2.731111.28 ± 2.707014.38 ± 3.0237

Adverse events

Collected over Day 1-11 in each period, along with the 29-36 day post final dose follow-up. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PF-07853578 1 mg (1mg) (Low Dosage Strength [LDS] Solution)0/5 (0%)0/5 (0%)1/5 (20%)
3 mg0/6 (0%)0/6 (0%)2/6 (33.3%)
8 mg0/5 (0%)0/5 (0%)3/5 (60%)
8 mg (Intermediate Dosage Strength [IDS] Solution)0/5 (0%)0/5 (0%)2/5 (40%)
10 mg0/5 (0%)0/5 (0%)2/5 (40%)
30 mg0/6 (0%)0/6 (0%)1/6 (16.7%)
100 mg0/5 (0%)0/5 (0%)0/5 (0%)
300 mg0/6 (0%)0/6 (0%)1/6 (16.7%)
300 mg Fed0/5 (0%)0/5 (0%)4/5 (80%)
500 mg0/4 (0%)0/4 (0%)0/4 (0%)
Placebo Fasted0/14 (0%)0/14 (0%)3/14 (21.4%)
Placebo Fed0/1 (0%)0/1 (0%)0/1 (0%)
Most frequent other events
Showing 10 of 19
Most frequent other events
EventPF-07853578 1 mg (1mg) (Low Dosage Strength [LDS] Solution)3 mg8 mg8 mg (Intermediate Dosage Strength [IDS] Solution)10 mg30 mg100 mg300 mg300 mg Fed500 mgPlacebo FastedPlacebo Fed
Application site irritationGeneral disorders0/51/60/50/51/51/60/50/62/50/40/140/1
Feeling hotGeneral disorders0/50/61/50/50/50/60/50/60/50/40/140/1
Upper respiratory tract infectionInfections and infestations0/50/60/51/50/50/60/50/60/50/40/140/1
MyalgiaMusculoskeletal and connective tissue disorders0/50/60/50/50/50/60/50/61/50/40/140/1
DizzinessNervous system disorders0/50/60/51/50/50/60/50/60/50/40/140/1
HeadacheNervous system disorders0/51/60/51/51/50/60/50/60/50/41/140/1
SomnolenceNervous system disorders0/50/61/50/50/50/60/50/60/50/40/140/1
Tension headacheNervous system disorders0/50/60/50/50/50/60/50/61/50/40/140/1
Oropharyngeal painRespiratory, thoracic and mediastinal disorders0/50/61/50/50/50/60/50/60/50/40/140/1
Dermatitis contactSkin and subcutaneous tissue disorders1/50/60/50/50/50/60/50/60/50/40/140/1

Baseline characteristics

Age, Customized
Age, Customized(Participants)Cohort 1Cohort 2Cohort 3Total
18-44 years65617
45-64 years2316
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1Cohort 2Cohort 3Total
Female1102
Male77721
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1Cohort 2Cohort 3Total
Hispanic or Latino1113
Not Hispanic or Latino77620
Unknown or Not Reported0000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cohort 1Cohort 2Cohort 3Total
White3418
Black or African American32510
Asian2114
American Indian or Alaska Native0101
08

Study locations

2 sites
  • New Haven Clinical Research Unit
    New Haven, Connecticut 06511, United States
  • Pfizer Clinical Research Unit - New Haven
    New Haven, Connecticut 06511, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2023 to primary completion in Dec 2023, 5 months.

Results were first posted in Jan 2025, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 25, 2023
First posted
Jun 6, 2023
StartActual
Jun 2, 2023
Primary completionActual
Dec 1, 2023
CompletionActual
Dec 1, 2023
Results first posted
Jan 3, 2025
Last update
Jan 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05890105
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jun 6, 2023
Start date
Jun 2, 2023
Primary completion
Dec 1, 2023
Completion
Dec 1, 2023
Results posted
Jan 3, 2025
Last update
Jan 3, 2025

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion